Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Asthma

Free Subscription Articles published in Eur Respir J Retrieve available abstracts of 107 articles: HTML format

Single Articles

September 2026
1. YAO P, Yang L, Liu D, He D, et al
   Distribution of blood eosinophil counts in the Chinese general population.
   Eur Respir J. 2026;68:2501570.
   PubMed     Abstract available
   
   
   August 2026
2. MATHESON AM, Willmering MM, Dournes G, Humbert M, et al
   Novel translational pulmonary MRI in paediatrics: a review of the past 10 years.
   Eur Respir J. 2026;68:2501619.
   PubMed     Abstract available
   
   
   
3. MCDONALD VM, Gibson PG
   Attacking asthma - viruses and azithromycin: connecting the mechanistic dots.
   Eur Respir J. 2026;68:2601038.
   PubMed    
   
   
   July 2026
4. AGARWAL R, Chaudhary D, Gupta SN, Dhar R, et al
   Safety and efficacy of inhaled itraconazole in adults with asthma and allergic bronchopulmonary aspergillosis (PUR1900-ABPA): a randomized, double-blind, parallel group, placebo-controlled, multicenter, phase 2 trial.
   Eur Respir J. 2026 Jul 16:2600058. doi: 10.1183/13993003.00058-2026.
   PubMed     Abstract available
   
   
   
5. BACHARIER LB, Busse WW, Jackson DJ, Katial RK, et al
   Critical flaws in: "Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study".
   Eur Respir J. 2026;68:2501565.
   PubMed     Abstract available
   
   
   June 2026
6. BOAKYE-DANKWA E, Kiddle SJ, Koo HN, Harper AR, et al
   A self-controlled case series to evaluate the effects of clinical trial eligibility criteria on biologic-associated reductions in severe asthma exacerbations: an analysis of the CHRONICLE Study.
   Eur Respir J. 2026 Jun 4:2502196. doi: 10.1183/13993003.02196-2025.
   PubMed     Abstract available
   
   
   
7. LEIGH MW, Shapiro AJ, Chawla KK, Hazucha MJ, et al
   Tidal breathing nasal nitric oxide measurement as a test for primary ciliary dyskinesia in young children.
   Eur Respir J. 2026;67:2501540.
   PubMed     Abstract available
   
   
   
8. ZHU Z
   Targeting eosinophil extracellular traps in asthma: a new axis for biologic intervention.
   Eur Respir J. 2026;67:2600452.
   PubMed    
   
   
   May 2026
9. PORTACCI A, Ventura L, Menzella F, Poto R, et al
   Small Airway Dysfunction May Mediate the Association Between Body Mass Index and Severe Asthma Exacerbations.
   Eur Respir J. 2026 May 21:2600150. doi: 10.1183/13993003.00150-2026.
   PubMed     Abstract available
   
   
   
10. GHANIZADA M, Malm Tillgren S, Menzel M, Praeger-Jahnsen L, et al
    Azithromycin enhances epithelial antiviral immunity in uncontrolled asthma: results from the AZIMUNE randomized controlled trial.
    Eur Respir J. 2026 May 7:2502441. doi: 10.1183/13993003.02441-2025.
    PubMed     Abstract available
    
    
    April 2026
11. DIAB N, Brister D, Kum E, Wahab M, et al
    Mepolizumab for the treatment of refractory chronic cough in patients with eosinophilic airways disease (MUCOSA): a randomised, double-blind, parallel-group, placebo-controlled trial.
    Eur Respir J. 2026;67:2501573.
    PubMed     Abstract available
    
    
    March 2026
12. GE E, Yu C, Lavigne E, Villeneuve PJ, et al
    Early-life greenness and childhood asthma and allergic rhinitis: An Ontario birth cohort study.
    Eur Respir J. 2026 Mar 12:2502272. doi: 10.1183/13993003.02272-2025.
    PubMed    
    
    
    
13. SORIANO JB, Perez de Llano LA
    Severe asthma: an indirect, subtle killer.
    Eur Respir J. 2026;67:2502402.
    PubMed    
    
    
    
14. BEASLEY R, Noble J
    Time to establish a consensus definition of clinical remission distinct from well-controlled asthma.
    Eur Respir J. 2026;67:2502384.
    PubMed    
    
    
    
15. ROBERTSON NM, Sharma AK, Yang M, Das SK, et al
    A multi-country cohort study evaluating the prevalence, risk factors, lung function and clinical outcomes of chronic bronchitis in low- and middle-income countries.
    Eur Respir J. 2026;67:2501435.
    PubMed     Abstract available
    
    
    
16. 
    ERJ Podcast March 2026: Mortality in severe asthma.
    Eur Respir J. 2026;67:26E6703.
    PubMed    
    
    
    February 2026
17. RIEMANN S, Matthys I, Maes T, Lapauw B, et al
    Obesity and asthma: obesity causes and aggravates asthma across the entire type-2 inflammation spectrum.
    Eur Respir J. 2026 Feb 19:2502687. doi: 10.1183/13993003.02687-2025.
    PubMed     Abstract available
    
    
    
18. FAHY JV
    The pathobiology and treatment of mucus plugs in asthma and COPD: state of the art.
    Eur Respir J. 2026 Feb 19:2502358. doi: 10.1183/13993003.02358-2025.
    PubMed     Abstract available
    
    
    
19. SUN X, Liao Y, Wu J, Liu Y, et al
    EcN-Sj16-Exo ameliorates experimental asthma by inhibiting eosinophil extracellular traps formation via N-WASP upregulation.
    Eur Respir J. 2026 Feb 19:2500948. doi: 10.1183/13993003.00948-2025.
    PubMed     Abstract available
    
    
    
20. LIPWORTH B, Suter P, Greig R
    Dupilumab and lymphoma risk among patients with asthma.
    Eur Respir J. 2026;67:2501380.
    PubMed    
    
    
    
21. 
    ERJ Podcast February 2026: Addressing the global challenges of COPD and asthma.
    Eur Respir J. 2026;67:26E6702.
    PubMed    
    
    
    
22. CELIS-PRECIADO CA, Couillard S
    Dupilumab and lymphoma risk in asthma.
    Eur Respir J. 2026;67:2501387.
    PubMed    
    
    
    December 2025
23. MURPHY VE
    Decreasing inhaled corticosteroids in pregnancy increases the risk for asthma exacerbations: time for new approaches to solve a decades-old problem.
    Eur Respir J. 2025;66:2501979.
    PubMed    
    
    
    November 2025
24. HAKANSSON KEJ, Hansen S, Soendergaard MB, von Bulow A, et al
    Long-term efficacy but rare sustained remission: Individual-level five-year stability in anti-IL5/Ralpha biologic therapy response for severe asthma.
    Eur Respir J. 2025 Nov 27:2500926. doi: 10.1183/13993003.00926-2025.
    PubMed     Abstract available
    
    
    
25. HALPIN DM, Masekela R, Vogelmeier CF, Ozoh OB, et al
    Addressing the global challenges of COPD and asthma: a shared vision from the global initiative for chronic obstructive pulmonary disease (GOLD) and the global initiative for asthma (GINA).
    Eur Respir J. 2025 Nov 6:2502244. doi: 10.1183/13993003.02244-2025.
    PubMed    
    
    
    
26. HANSEN S, von Bulow A, Cooper A, Sandin P, et al
    Mortality in Severe Asthma - results from the NORDSTAR cohort.
    Eur Respir J. 2025 Nov 6:2501289. doi: 10.1183/13993003.01289-2025.
    PubMed     Abstract available
    
    
    October 2025
27. HOWELL I, Mahdi M, Mahmood HR, Bermejo-Sanchez L, et al
    Exhaled nitric oxide (FeNO) and the response to prednisolone for asthma attacks in patients treated with anti-IL5/5Ralpha therapy: a prospective observational study.
    Eur Respir J. 2025 Oct 9:2501229. doi: 10.1183/13993003.01229-2025.
    PubMed    
    
    
    
28. ZHU Z, Liu C, Ober C, Camargo CA Jr, et al
    Gene-environment interaction at 17q12-q21 locus and its role in asthma pathogenesis.
    Eur Respir J. 2025;66:2501232.
    PubMed    
    
    
    
29. ANNESI-MAESANO I, Bayram H, Cecchi L, Croft D, et al
    Natural disasters and respiratory health.
    Eur Respir J. 2025;66:2402563.
    PubMed     Abstract available
    
    
    September 2025
30. DAVIES TJ, Pavord ID
    Lymphoma in patients with asthma treated with dupilumab: much ado about nothing?
    Eur Respir J. 2025;66:2501321.
    PubMed    
    
    
    August 2025
31. LEE B, Wong E, Tan T, Rupani H, et al
    Pregnancy, asthma and exacerbations: a population-based cohort.
    Eur Respir J. 2025 Aug 28:2501327. doi: 10.1183/13993003.01327-2025.
    PubMed     Abstract available
    
    
    
32. WILKINSON TMA, Akuthota P
    CompEx Asthma: is it time for a change in clinical trials?
    Eur Respir J. 2025 Aug 21:2500470. doi: 10.1183/13993003.00470-2025.
    PubMed    
    
    
    July 2025
33. LIU KY, Sie JJ, Gao Y, Lo YL, et al
    Functional sequence variants of intergenic long non-coding RNA on Chromosome 17q21 are associated with asthma.
    Eur Respir J. 2025 Jul 3:2500847. doi: 10.1183/13993003.00847-2025.
    PubMed     Abstract available
    
    
    
34. MENON L, Blakey J, Ramakrishnan S
    Type 2 inflammatory biomarkers in asthma and COPD: what we think we know.
    Eur Respir J. 2025;66:2500685.
    PubMed    
    
    
    
35. CELIS-PRECIADO C, Lemaire-Paquette S, Lachapelle P, Couillard S, et al
    Reply to: Type 2 inflammatory biomarkers in asthma and COPD: what we think we know.
    Eur Respir J. 2025;66:2500949.
    PubMed    
    
    
    June 2025
36. SHENG-KAI MA K, Brumbaugh B, Saff RR, Phipatanakul W, et al
    Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study.
    Eur Respir J. 2025 Jun 19:2500139. doi: 10.1183/13993003.00139-2025.
    PubMed     Abstract available
    
    
    May 2025
37. GIRAULT A, Le A, Gonsard A, Abou Taam R, et al
    ChatGPT and Other Large Language Models for Parents' Questions About Childhood Asthma: A Comparative Study.
    Eur Respir J. 2025 May 15:2500254. doi: 10.1183/13993003.00254-2025.
    PubMed    
    
    
    
38. BUSSE WW, O'Byrne PM
    Are systemic corticosteroids needed for all asthma exacerbations?
    Eur Respir J. 2025;65:2500370.
    PubMed    
    
    
    
39. 
    ERJ Podcast May 2026: Mucus plugs in asthma and COPD.
    Eur Respir J. 2026;67:26E6705.
    PubMed    
    
    
    April 2025
40. YANG F, Bossios A
    Who really responds to asthma biologics? The clue lies in the journey before treatment.
    Eur Respir J. 2025;65:2500044.
    PubMed    
    
    
    
41. 
    "Epigenomic partitioning of a polygenic risk score for asthma reveals distinct genetically driven disease pathways." B. Stikker, L. Trap, B. Sedaghati-Khayat, et al. Eur Respir J 2024; 64: 2302059.
    Eur Respir J. 2025;65:2352059.
    PubMed    
    
    
    
42. KOURID MI, Couillard S
    Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?
    Eur Respir J. 2025;65:2500153.
    PubMed    
    
    
    
43. HAMADA Y, Thomas D, Gibson PG
    Reply to: Critique of logistic regression in analysing treatment response in severe eosinophilic asthma.
    Eur Respir J. 2025;65:2500516.
    PubMed    
    
    
    
44. 
    "Advancing patient-centred care in measuring response to biologics in severe asthma." Vanesa Bellou. Eur Respir J 2025; 65: 2402113.
    Eur Respir J. 2025;65:2452113.
    PubMed    
    
    
    
45. TAKEFUJI Y
    Critique of logistic regression in analysing treatment response in severe eosinophilic asthma.
    Eur Respir J. 2025;65:2500423.
    PubMed    
    
    
    March 2025
46. BELLOU V
    Advancing patient-centred care in measuring response to biologics in severe asthma.
    Eur Respir J. 2025;65:2402113.
    PubMed    
    
    
    February 2025
47. BOURDIN A, Nogue E, Matzner-Lober E, Malafaye N, et al
    What can lockdowns tell us about the underlying causes of asthma exacerbations? A retrospective cohort study.
    Eur Respir J. 2025 Feb 27:2402264. doi: 10.1183/13993003.02264-2024.
    PubMed    
    
    
    
48. CELIS-PRECIADO C, Leclerc S, Duval M, Cliche DO, et al
    Phenotyping the Responses to Systemic Corticosteroids in the Management of Asthma Attacks (PRISMA).
    Eur Respir J. 2025 Feb 13:2402391. doi: 10.1183/13993003.02391-2024.
    PubMed     Abstract available
    
    
    
49. MAILHOT-LAROUCHE S, Busby J, Couillard S
    Response and remission in asthma with tezepelumab: overlapping concepts informing on type-2 inflammatory-dependent treatment effects.
    Eur Respir J. 2025;65:2402057.
    PubMed    
    
    
    
50. MARTIN N, Wechsler ME, Brightling CE
    Reply to: Response and remission in asthma with tezepelumab: overlapping concepts informing on type-2 inflammatory-dependent treatment effects.
    Eur Respir J. 2025;65:2402434.
    PubMed     Abstract available
    
    
    January 2025
51. DEITEREN A, Krupka E, Bontinck L, Imberdis K, et al
    A proof-of-mechanism trial in asthma with lunsekimig, a bispecific nanobody(R) molecule.
    Eur Respir J. 2025 Jan 30:2401461. doi: 10.1183/13993003.01461-2024.
    PubMed     Abstract available
    
    
    
52. SOENDERGAARD MB, Hjortdahl F, Hansen S, Bjerrum AS, et al
    Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthma.
    Eur Respir J. 2025 Jan 9:2401497. doi: 10.1183/13993003.01497-2024.
    PubMed     Abstract available
    
    
    
53. NOLASCO S, Mukherjee M, Nair P
    Trajectories of responses to mepolizumab in severe asthma.
    Eur Respir J. 2025;65:2402023.
    PubMed    
    
    
    
54. 
    ERJ Podcast January 2025: Treatment response to mepolizumab in severe eosinophilic asthma.
    Eur Respir J. 2025;65:25E6501.
    PubMed    
    
    
    December 2024
55. PIZZICHINI MMM, Pizzichini E
    Is asthma remission an important clinical outcome in asthma management?
    Eur Respir J. 2024;64:2401908.
    PubMed    
    
    
    
56. OKTELIK FB, Benamar M
    Glycerolipids disrupt regulatory T-cells in asthma.
    Eur Respir J. 2024;64:2401386.
    PubMed    
    
    
    November 2024
57. CHAN AHY, De Keyser HH, Horne R, Szefler SJ, et al
    Defining adherence phenotype and endotypes to personalise asthma management.
    Eur Respir J. 2024 Nov 27:2401357. doi: 10.1183/13993003.01357-2024.
    PubMed    
    
    
    
58. KHALEVA E, Brightling C, Eiwegger T, Altraja A, et al
    Patient-centred composite scores as tools for assesment of response to biological therapy for paediatric and adult severe asthma.
    Eur Respir J. 2024 Nov 7:2400691. doi: 10.1183/13993003.00691-2024.
    PubMed     Abstract available
    
    
    
59. POLVERINO F, Woodruff PG
    Radiomultiomics: pioneering precision medicine for severe asthma.
    Eur Respir J. 2024;64:2401639.
    PubMed    
    
    
    October 2024
60. HAMADA Y, Thomas D, Harvey ES, Stevens S, et al
    Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma.
    Eur Respir J. 2024 Oct 10:2400782. doi: 10.1183/13993003.00782-2024.
    PubMed     Abstract available
    
    
    
61. KERMANI NZ, Chung KF, Macis G, Santini G, et al
    Radiomultiomics: quantitative CT clusters of severe asthma associated with multi-omics.
    Eur Respir J. 2024 Oct 10:2400207. doi: 10.1183/13993003.00207-2024.
    PubMed     Abstract available
    
    
    
62. MCSORLEY HJ
    RIPK2 inhibition gets the NOD for asthma.
    Eur Respir J. 2024;64:2401372.
    PubMed    
    
    
    September 2024
63. WECHSLER ME, Brusselle G, Virchow JC, Bourdin A, et al
    Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies.
    Eur Respir J. 2024 Sep 26:2400316. doi: 10.1183/13993003.00316-2024.
    PubMed     Abstract available
    
    
    
64. ZHU Z, Shibata R, Hoffman KL, Cormier J, et al
    Integrated nasopharyngeal airway metagenome and asthma genetic risk endotyping of severe bronchiolitis in infancy and risk of childhood asthma.
    Eur Respir J. 2024 Sep 26:2401130. doi: 10.1183/13993003.01130-2024.
    PubMed     Abstract available
    
    
    
65. GIBSON PG, McDonald VM
    Integrating hot topics and implementation of treatable traits in asthma.
    Eur Respir J. 2024 Sep 10:2400861. doi: 10.1183/13993003.00861-2024.
    PubMed     Abstract available
    
    
    
66. LAHOUSSE L
    Overweight and dysanapsis in childhood asthma.
    Eur Respir J. 2024;64:2401164.
    PubMed    
    
    
    
67. MAKRINIOTI H, Fainardi V, Bonnelykke K, Custovic A, et al
    European Respiratory Society statement on preschool wheezing disorders: updated definitions, knowledge gaps and proposed future research directions.
    Eur Respir J. 2024;64:2400624.
    PubMed     Abstract available
    
    
    
68. WENZEL SE
    Allergen challenge, eosinophils and the long road to asthma endotypes.
    Eur Respir J. 2024;64:2401316.
    PubMed    
    
    
    August 2024
69. VERSI A, Azim A, Ivan FX, Abdel-Aziz MI, et al
    Host-microbial interactions differ with age of asthma onset.
    Eur Respir J. 2024 Aug 30:2400428. doi: 10.1183/13993003.00428-2024.
    PubMed    
    
    
    
70. AILI A, Wang Y, Shang Y, Zhang L, et al
    LPG 18:0 is a general biomarker of asthma and inhibits the differentiation and function of regulatory T cells.
    Eur Respir J. 2024 Aug 15:2301752. doi: 10.1183/13993003.01752-2023.
    PubMed     Abstract available
    
    
    
71. ABDO M, Pedersen F, Kirsten AM, Trinkmann F, et al
    Association of airway inflammation and smoking status with IL-33 level in sputum of patients with asthma or COPD.
    Eur Respir J. 2024 Aug 15:2400347. doi: 10.1183/13993003.00347-2024.
    PubMed    
    
    
    
72. ALVAREZ-SIMON D, Ait Yahia S, Audousset C, Fanton d'Andon M, et al
    Local Receptor-interacting Protein Kinase 2 inhibition mitigates HDM-induced asthma.
    Eur Respir J. 2024 Aug 8:2302288. doi: 10.1183/13993003.02288-2023.
    PubMed     Abstract available
    
    
    
73. BLOOM C
    The burden of zoster in asthma: what is left to learn?
    Eur Respir J. 2024;64:2401300.
    PubMed    
    
    
    
74. KHURANA S, Georas SN
    Stepping down biologics in asthma: is it time to challenge the status quo?
    Eur Respir J. 2024;64:2401168.
    PubMed    
    
    
    July 2024
75. GAUVREAU GM, Sehmi R, FitzGerald JM, Leigh R, et al
    Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled, trial.
    Eur Respir J. 2024 Jul 26:2400512. doi: 10.1183/13993003.00512-2024.
    PubMed     Abstract available
    
    
    
76. WILKINSON A, Woodcock A
    High-quality and low-carbon asthma care go hand in hand.
    Eur Respir J. 2024;64:2400638.
    PubMed    
    
    
    
77. SOUMAGNE T, Degano B
    Real world evidence in asthma: what to expect beyond randomised controlled trials?
    Eur Respir J. 2024;64:2400716.
    PubMed    
    
    
    
78. LU J, Wang Z
    Mendelian randomisation supports no evidence of the association between asthma and coronary heart disease in East Asians.
    Eur Respir J. 2024;64:2400628.
    PubMed    
    
    
    June 2024
79. MORTIMER KJ, Cruz AA, Sepulveda-Pachon IT, Jorga A, et al
    Global herpes zoster burden in adults with asthma: a systematic review and meta-analysis.
    Eur Respir J. 2024 Jun 20:2400462. doi: 10.1183/13993003.00462-2024.
    PubMed     Abstract available
    
    
    
80. STIKKER B, Trap L, Sedaghati-Khayat B, de Bruijn MJW, et al
    Epigenomic partitioning of a polygenic risk score for asthma reveals distinct genetically driven disease pathways.
    Eur Respir J. 2024 Jun 20:2302059. doi: 10.1183/13993003.02059-2023.
    PubMed     Abstract available
    
    
    
81. SAIKUMAR JAYALATHA AK, Ketelaar ME, Hesse L, Badi YE, et al
    IL-33 induced gene expression in activated Th2 effector cells is dependent on IL-1RL1 haplotype and asthma status.
    Eur Respir J. 2024 Jun 6:2400005. doi: 10.1183/13993003.00005-2024.
    PubMed    
    
    
    
82. VERBANCK S, Eddy RL, McIntosh MJ, Parraga G, et al
    Missing airways, ventilation defects and conductive airway physiology in asthma.
    Eur Respir J. 2024 Jun 6:2400242. doi: 10.1183/13993003.00242-2024.
    PubMed    
    
    
    
83. SOENDERGAARD MB, Bjerrum AS, Rasmussen LM, Lock-Johansson S, et al
    OPTIMAL: Titration of anti-IL5 biologics in severe asthma - An open label randomised controlled trial.
    Eur Respir J. 2024 Jun 6:2400404. doi: 10.1183/13993003.00404-2024.
    PubMed     Abstract available
    
    
    
84. MCDOWELL PJ, McDowell R, Busby J, Eastwood MC, et al
    Clinical remission with biologic therapies in severe asthma: a matter of definition.
    Eur Respir J. 2024;63:2400160.
    PubMed     Abstract available
    
    
    
85. BEASLEY R, Noble J, Weatherall M
    The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma.
    Eur Respir J. 2024;63:2400523.
    PubMed     Abstract available
    
    
    May 2024
86. KJELDGAARD JENSEN S, Tingskov Pedersen CE, Fischer-Rasmussen K, Elsner Melgaard M, et al
    Genetic predisposition to high BMI increases risk of early life respiratory infections and episodes of severe wheeze and asthma.
    Eur Respir J. 2024 May 29:2400169. doi: 10.1183/13993003.00169-2024.
    PubMed     Abstract available
    
    
    
87. LIU T, Prescott WG, Zhou X
    Advances in Non-Type 2 Asthma in the Severe Cases: from molecular insights to novel treatment strategies.
    Eur Respir J. 2024 May 2:2300826. doi: 10.1183/13993003.00826-2023.
    PubMed     Abstract available
    
    
    
88. RAMAKRISHNAN S, Montgomery B, Pavord ID
    Blood eosinophils and lung function loss: from passive prediction to active prevention?
    Eur Respir J. 2024;63:2400812.
    PubMed    
    
    
    
89. BUSH A, Randerath W, Roche N
    As needed ICS/formoterol: not all of Europe is equal.
    Eur Respir J. 2024;63:2400408.
    PubMed    
    
    
    
90. HONG YS, Park HY, Ryu S, Shin SH, et al
    The association of blood eosinophil counts and FEV(1) decline: a cohort study.
    Eur Respir J. 2024;63:2301037.
    PubMed     Abstract available
    
    
    
91. POLVERINO F, Sin DD
    Type 2 airway inflammation in COPD.
    Eur Respir J. 2024;63:2400150.
    PubMed     Abstract available
    
    
    April 2024
92. HATTER L, Holliday M, Eathorne A, Bruce P, et al
    The carbon footprint of as-needed budesonide-formoterol in mild asthma: a post hoc analysis.
    Eur Respir J. 2024 Apr 12:2301705. doi: 10.1183/13993003.01705-2023.
    PubMed     Abstract available
    
    
    
93. JACKSON DJ, Pelaia G, Emmanuel B, Tran TN, et al
    Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme.
    Eur Respir J. 2024 Apr 4:2301521. doi: 10.1183/13993003.01521-2023.
    PubMed     Abstract available
    
    
    
94. KRISHNAN JA, Buhl R
    As-needed ICS/formoterol or as-needed SABA in mild asthma?
    Eur Respir J. 2024;63:2302308.
    PubMed    
    
    
    
95. PAPI A, Ferreira DS, Tonia T, Schleich F, et al
    Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?
    Eur Respir J. 2024;63:2400395.
    PubMed    
    
    
    
96. STANESCU C, Talarico R, Weichenthal S, Villeneuve PJ, et al
    Early life exposure to pollens and increased risks of childhood asthma: a prospective cohort study in Ontario children.
    Eur Respir J. 2024;63:2301568.
    PubMed     Abstract available
    
    
    
97. VARRICCHI G, Brightling CE, Grainge C, Lambrecht BN, et al
    Airway remodelling in asthma and the epithelium: on the edge of a new era.
    Eur Respir J. 2024;63:2301619.
    PubMed     Abstract available
    
    
    
98. BLOOM CI
    Reply: Asthma and cardiovascular disease: the strength of triangulation.
    Eur Respir J. 2024;63:2400554.
    PubMed    
    
    
    
99. TATTERSALL MC, Gangnon RE, Jarjour NN
    Asthma and cardiovascular disease: embracing disease heterogeneity is required.
    Eur Respir J. 2024;63:2400469.
    PubMed    
    
    
    
100. 
     ERJ Podcast April 2024: Allergic bronchopulmonary aspergillosis.
     Eur Respir J. 2024;63:24E6304.
     PubMed    
     
     
     March 2024
101. LIU T, Liu S, Rui X, Cao Y, et al
     Gasdermin B, an asthma-susceptibility gene, promotes MAVS-TBK1 signaling and airway inflammation.
     Eur Respir J. 2024 Mar 21:2301232. doi: 10.1183/13993003.01232-2023.
     PubMed     Abstract available
     
     
     
102. LUO RG, Wu YF, Lu HW, Weng D, et al
     Th2-skewed peripheral T helper cells drives B cells in allergic bronchopulmonary aspergillosis.
     Eur Respir J. 2024 Mar 21:2400386. doi: 10.1183/13993003.00386-2024.
     PubMed     Abstract available
     
     
     
103. RUSSELL RJ, Boulet LP, Brightling CE, Pavord ID, et al
     The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma.
     Eur Respir J. 2024 Mar 7:2301397. doi: 10.1183/13993003.01397-2023.
     PubMed     Abstract available
     
     
     
104. 
     "Asthma and incident coronary heart disease: an observational and Mendelian randomisation study." C.A. Valencia-Hernandez, F. Del Greco M, V. Sundaram, et al. Eur Respir J 2023; 62: 2301788.
     Eur Respir J. 2024;63:2351788.
     PubMed    
     
     
     
105. 
     "Aberrant anti-viral response of natural killer cells in severe asthma." J. Devulder, C. Chenivesse, V. Ledroit, et al. Eur Respir J 2020; 55: 1802422.
     Eur Respir J. 2024;63:1852422.
     PubMed    
     
     
     February 2024
106. WANG T, Duan W, Jia X, Huang X, et al
     Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study.
     Eur Respir J. 2024;63:2301720.
     PubMed     Abstract available
     
     
     August 2023
107. 
     ERJ Podcast August 2024: Titration of anti-IL-5 biologics in severe asthma.
     Eur Respir J. 2024;64:24E6402.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Asthma is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum